{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:41:21Z","timestamp":1793047281743,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":275,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1111\/bjd.13343","type":"journal-article","created":{"date-parts":[[2014,8,16]],"date-time":"2014-08-16T03:53:32Z","timestamp":1408161212000},"page":"244-252","source":"Crossref","is-referenced-by-count":251,"title":["Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris"],"prefix":"10.1093","volume":"172","author":[{"given":"R.","family":"Gniadecki","sequence":"first","affiliation":[{"name":"Department of Dermatology; Bispebjerg Hospital; Bispebjerg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Bispebjerg Hospital; Bispebjerg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Bryld","sequence":"additional","affiliation":[{"name":"Department of Dermatology Roskilde Hospital; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Marselisborg Hospital; Aarhus University; Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lasthein","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Odense Hospital; University of Southern Denmark; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology Gentofte Hospital; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,30]]},"reference":[{"issue":"Suppl.","key":"10.1111\/bjd.13343-BIB0001|bjd13343-cit-0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0002|bjd13343-cit-0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3\u00a0years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.13343-BIB0003|bjd13343-cit-0003","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.13343-BIB0004|bjd13343-cit-0004","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3\u00a0years","volume":"166","author":"Kimball","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0005|bjd13343-cit-0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0006|bjd13343-cit-0006","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0007|bjd13343-cit-0007","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.12543","article-title":"Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre","volume":"169","author":"L\u00f3pez-Ferrer","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0008|bjd13343-cit-0008","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.12648","article-title":"Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis","volume":"170","author":"Reek","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0009|bjd13343-cit-0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.13343-BIB0010|bjd13343-cit-0010","first-page":"246","article-title":"Essential factors influencing health-related-quality of life in psoriasis","volume":"13","author":"Mehren","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.13343-BIB0011|bjd13343-cit-0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjd.13001","article-title":"Drug survival not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis","volume":"171","author":"Menting","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0012|bjd13343-cit-0012","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bjd.13087","article-title":"\u2018Happy\u2019 drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care - results from the BioCAPTURE network","volume":"171","author":"van den Reek","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0013|bjd13343-cit-0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.13343-BIB0014|bjd13343-cit-0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000316184","article-title":"The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab","volume":"221","author":"Papoutsaki","year":"2010","journal-title":"Dermatology"},{"key":"10.1111\/bjd.13343-BIB0015|bjd13343-cit-0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2340\/00015555-1230","article-title":"Dose-creep of infliximab during psoriasis treatment: an observational study","volume":"92","author":"Mehren","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.13343-BIB0016|bjd13343-cit-0016","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5\u00a0years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.13343-BIB0017|bjd13343-cit-0017","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1468-3083.2010.03914.x","article-title":"Responses to ustekinumab in the anti-TNF agent-na\u00efve vs. anti-TNF agent-exposed patients with psoriasis vulgaris","volume":"25","author":"Clemmensen","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.13343-BIB0018|bjd13343-cit-0018","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjd.12643","article-title":"One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis","volume":"170","author":"Reich","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.13343-BIB0019|bjd13343-cit-0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.13343-BIB0020|bjd13343-cit-0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.13343-BIB0021|bjd13343-cit-0021","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with immunogenicity of biologicals: assessment and clinical relevance","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/bjd.13343-BIB0022|bjd13343-cit-0022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.13343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.13343\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:11:52Z","timestamp":1676365912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/172\/1\/244\/6615837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.13343","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718535236.793498913","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11,30]]}}}